A Phase 1 interventional study of BI 730357 and Placebo in Healthy and Psoriasis, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Psoriasis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Psoriasis · Boehringer Ingelheim.
Among the 20 studies in Psoriasis by Boehringer Ingelheim, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 20 studies in Psoriasis by Boehringer Ingelheim is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 116 across the 18 interventional studies, 26 across the 2 observational. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Psoriasis by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase Ib evaluation of the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) properties of Multiple Rising Dose (MRD) administration of BI 730357 to healthy volunteers for up to 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were orally administered BI 730357 25 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
Drug: BI 730357
Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after a fasting period of at least 6 hours.
Drug: Placebo
Subjects were orally administered matching Placebo to BI 730357, film-coated tablet after the intake of a standard continental breakfast.
Drug: Placebo
Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours.
Drug: BI 730357
Subject was orally administered mixed treatment of BI 730357 50 mg and placebo, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
Drug: BI 730357 · Drug: Placebo
Subjects were orally administered BI 730357 50 mg, film-coated tablet once daily over 14 days after the intake of a standard continental breakfast.
Drug: BI 730357
Subjects were orally administered BI 730357 100 mg, film-coated tablet once daily over 14 days after a fasting period of at least 6 hours
Drug: BI 730357
Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after a fasting period of at least 6 hours
Drug: BI 730357
Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 200 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.
Drug: BI 730357 · Drug: Midazolam
Subjects were orally administered a microdose of midazolam 75 microgram (75 μg) solution for injection, orally on Day -1, and prior receiving BI 730357 on Days 3, and 14. Subjects were orally administered BI 730357 400 mg, film-coated tablet once daily over 28 days after the intake of a standard continental breakfast.
Drug: BI 730357 · Drug: Midazolam
Number of Subjects With Drug-related Adverse Events (AEs)
Number of subjects with drug-related Adverse Events (AEs) assessed by the investigator.
Time frame: From first drug administration until 7 days after last dose, up to 21 days (for 25, 50 and 100 mg dose groups) and up to 35 days (for 200 and 400 mg dose groups)
Area Under the Concentration-time Curve of the Analyte BI 730357 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCtau,1)
Area under the concentration-time curve of the analyte BI 730357 in plasma over a uniform dosing interval tau after administration of the first dose (AUCtau,1). In this study AUCtau,1 = AUC0-24
Time frame: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h and 23.5h after first dosing on Day1.
Maximum Measured Concentration of the Analyte BI 730357 in Plasma After Administration of the First Dose (Cmax)
Maximum measured concentration of the analyte BI 730357 in plasma after administration of the first dose (Cmax)
Time frame: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h and 23.5h after first dosing on Day1.
Area Under the Concentration-time Curve of BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After Last Dose Administration.
Area under the concentration-time curve of BI 730357 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.
Time frame: Day 14 and Day 28 (Please refer description for the time frame in detail)
Maximum Measured Concentration of the Analyte BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ After the Last Dose (Cmax,ss)
Maximum measured concentration of BI 730357 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups:-0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.
Time frame: Day 14 and Day 28 (Please refer description for the time frame in detail)
Randomised, placebo-controlled, double-blind design investigating multiple rising doses
| Milestone | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50mg/Placebo | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 11 | 9 | 9 | 9 | 1 | 8 | 9 | 9 | 9 | 9 |
| Completed | 10 | 8 | 8 | 9 | 1 | 8 | 8 | 9 | 9 | 8 |
| Not completed | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other than stated above | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Number of subjects with drug-related Adverse Events (AEs) assessed by the investigator.
| Participants | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Drug-related Adverse Events (AEs) | 4 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 2 |
Area under the concentration-time curve of the analyte BI 730357 in plasma over a uniform dosing interval tau after administration of the first dose (AUCtau,1). In this study AUCtau,1 = AUC0-24
| Nanomole (nmol)·hour (h)/ liter(L) | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte BI 730357 in Plasma Over a Uniform Dosing Interval Tau After Administration of the First Dose (AUCtau,1) | 2150 ± 31.2 | 3590 ± 34.4 | 4620 ± 27.9 | 6650 ± 26.4 | 9240 ± 32.2 | 11900 ± 22.6 | 15600 ± 24.5 |
Maximum measured concentration of the analyte BI 730357 in plasma after administration of the first dose (Cmax)
| Nanomole (nmol)/liter(L) | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|
| Maximum Measured Concentration of the Analyte BI 730357 in Plasma After Administration of the First Dose (Cmax) | 143 ± 25.4 | 247 ± 37.6 | 368 ± 34.8 | 408 ± 32.5 | 537 ± 26.8 | 953 ± 36.5 | 1320 ± 24.0 |
Area under the concentration-time curve of BI 730357 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups: -0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.
| Nanomole (nmol)·hour (h)/ liter(L) | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After Last Dose Administration. | 4200 ± 50.0 | 7550 ± 30.3 | 9950 ± 29.4 | 14100 ± 24.5 | 14600 ± 45.0 | 29700 ± 30.0 | 31400 ± 38.2 |
Maximum measured concentration of BI 730357 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after last dose administration is reported. τ for 25, 50, 100 , 200 and 400 mg dose groups is: 24 hours (h). Time Frame: For 25, 50, and 100 mg dose groups:-0.5h before dosing and 0.25h, 0.5h, 1h, 1.5h, 2 h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 12h, 23.5h, 47.5 and 71.5 h after last dose on Day14. For 200 and 400 mg dose groups: -0.5h before last dose and 1.0h, 2.0h, 3.0h, 4.0h and 24.0h after last dose on Day28.
| Nanomole (nmol)/ liter(L) | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|
| Maximum Measured Concentration of the Analyte BI 730357 in Plasma at Steady State Over a Uniform Dosing Interval τ After the Last Dose (Cmax,ss) | 277 ± 37.6 | 474 ± 26.7 | 697 ± 26.5 | 793 ± 29.2 | 948 ± 37.5 | 1840 ± 27.8 | 2260 ± 25.8 |
Collected over From first drug administration until 7 days after last dose, up to 21 days (for 25, 50 and 100 mg dose groups) and up to 35 days (for 200 and 400 mg dose groups). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Fast | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Placebo Fed | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| BI 730357 25 mg Fast | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| BI 730357 50 mg Fast | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| BI 730357 50 mg Fed | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| BI 730357 100 mg Fast | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| BI 730357 200 mg Fast | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| BI 730357 200 mg Fed | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| BI 730357 400 mg Fed | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Event | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/12 | 3/9 | 2/9 | 3/10 | 1/8 | 2/9 | 4/9 | 2/9 | 1/9 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/9 | 1/9 | 1/10 | 2/8 | 2/9 | 2/9 | 0/9 | 0/9 |
| NasopharyngitisInfections and infestations | 2/12 | 0/9 | 2/9 | 1/10 | 2/8 | 0/9 | 1/9 | 0/9 | 1/9 |
| DizzinessNervous system disorders | 2/12 | 1/9 | 0/9 | 0/10 | 0/8 | 0/9 | 1/9 | 0/9 | 2/9 |
| Neck painMusculoskeletal and connective tissue disorders | 0/12 | 0/9 | 0/9 | 0/10 | 0/8 | 0/9 | 2/9 | 0/9 | 0/9 |
| ErythemaSkin and subcutaneous tissue disorders | 0/12 | 0/9 | 0/9 | 0/10 | 0/8 | 0/9 | 0/9 | 0/9 | 2/9 |
| DyspepsiaGastrointestinal disorders | 0/12 | 0/9 | 1/9 | 0/10 | 1/8 | 0/9 | 0/9 | 0/9 | 0/9 |
| NauseaGastrointestinal disorders | 1/12 | 0/9 | 0/9 | 0/10 | 1/8 | 0/9 | 0/9 | 0/9 | 0/9 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/12 | 0/9 | 0/9 | 0/10 | 1/8 | 0/9 | 0/9 | 0/9 | 0/9 |
| Seborrhoeic dermatitisSkin and subcutaneous tissue disorders | 0/12 | 0/9 | 0/9 | 0/10 | 1/8 | 0/9 | 0/9 | 0/9 | 0/9 |
Treated set (TS): all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment
| Age, Continuous(Years) | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50mg/Placebo | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 32.8 ± 7.6 | 26.8 ± 5.4 | 33.3 ± 7.0 | 32.3 ± 7.7 | 25.0 ± NA | 25.4 ± 3.6 | 27.3 ± 2.2 | 27.1 ± 5.9 | 25.6 ± 4.4 | 30.6 ± 8.5 | 29.1 ± 6.6 |
| Sex: Female, Male(Participants) | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50mg/Placebo | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 11 | 9 | 9 | 9 | 1 | 8 | 9 | 9 | 9 | 9 | 83 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50mg/Placebo | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 11 | 9 | 9 | 8 | 1 | 8 | 9 | 9 | 9 | 9 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Fast | Placebo Fed | BI 730357 25 mg Fast | BI 730357 50 mg Fast | BI 730357 50mg/Placebo | BI 730357 50 mg Fed | BI 730357 100 mg Fast | BI 730357 200 mg Fast | BI 730357 200 mg Fed | BI 730357 400 mg Fed | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 4 |
| White | 10 | 7 | 9 | 8 | 1 | 7 | 8 | 8 | 7 | 9 | 74 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Jan 2018 to primary completion in Aug 2018, 7 months.
Results were first posted in Sep 2023, 5 years after primary completion.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevurogant